DSM-Firmenich reported Q3 core profit exceeding consensus and upgraded full-year growth guidance to roughly 5%. Key drivers include new contract wins and robust perfumery and beauty sales. The fragrance and beauty ingredient sectors show strength, supporting positive sentiment across related specialty chemical value chains. Demand stability suggests resilience in consumer-facing downstream applications. Improved profitability strengthens DSM-Firmenich's competitive standing but necessitates sustained execution to meet higher growth targets. Maintaining margin levels will remain pivotal amidst operational scaling.
13 articles
DSM-Firmenich reported Q3 core profit slightly above consensus and raised its full-year growth forecast to around 5%, driven by contract wins and strong perfumery & beauty sales.
DSM-Firmenich opened a new integrated office in Jakarta and expanded its Karawang production base to enhance capabilities in flavors, beauty, and food ingredients. The facility utilizes green power an
DSM-Firmenich opened a new Jakarta office and expanded its Karawang manufacturing facility in Indonesia to boost production capacity and local innovation for flavors, fragrances, and nutrition. The pr
DSM-Firmenich initiated patent infringement litigation in China against multiple entities regarding unauthorized sclareol production. The company seeks court orders to cease infringement and secure co
DSM-Firmenich reported a 6% drop in Q1 adjusted EBITDA and 3% sales decline due to currency effects, yet maintained full-year guidance citing robust underlying volumes in perfumery and beauty segments
DSM-Firmenich reported Q1 core profit matching forecasts, with adjusted EBITDA reaching €434 million. Strong demand for perfumery and beauty products drove the results.
DSM-Firmenich China President Zhou Tao outlines the company's "15th Five-Year Plan" strategy, highlighting new investments in fermentation and fragrance facilities to meet growing demand in nutrition
DSM-Firmenich forecasts higher margins and organic growth for 2026, factoring in current economic challenges while assuming no prolonged impact from the Middle East conflict.
DSM-Firmenich reported a decline in Q4 sales driven by negative currency impacts despite organic growth, with a full-year outlook scheduled for release in March 2026.
CVC Capital Partners agreed to purchase DSM-Firmenich's animal nutrition and health business for €2.2 billion, finalizing the company's shift toward consumer-facing nutrition, health, and beauty opera
DSM-Firmenich and Korea’s ASTech have forged a partnership to advance the global UV filters market by establishing a stable supply chain for UV filter ingredients.
DSM-Firmenich completed its €1.08 billion share buyback for capital reduction, cutting issued shares by 4.5% in Q1 2026.
DSM-Firmenich missed Q3 estimates and trimmed guidance due to currency effects, reporting a 5% YoY revenue decline despite 2% organic growth supported by self-help programs.
ChemBrief